Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANI Names Interim CEO As Przybyl Prepares To Step Down

As Company Also Reveals First-Quarter Results

Executive Summary

ANI revealed last month that long-serving company head Arthur Przybyl would be departing after 11 years at the top. The US-based player has just announced its interim chief as it reported first-quarter sales, following the landmark US portfolio acquisition from Amerigen in January, and made a major announcement for its full-year financial guidance.

You may also be interested in...



ANI CEO Przybyl To Depart After 11 Years

ANI Pharmaceuticals has been steered by former Akorn head Arthur Przybyl since March 2009. But he will bring the curtain down on his time with the company next month, as the company recruits his replacement ahead of a key branded product launch.

ANI Grabs 23 US Products From Amerigen

In a deal worth up to $77.5m, ANI has acquired rights to 12 marketed generics in the US, as well as to another 11 pipeline products, from Amerigen.

Celltrion Selected For Korean-Made Insulin Biosimilar

Korean firm Celltrion is aiming to move production of insulin pens inside Korea “for the first time” and break the stranglehold of Big Pharma insulin players in the market by launching a biosimilar product in 2025.

Topics

Related Companies

UsernamePublicRestriction

Register

SC066183

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel